Searched for
DRUG MAKER DIVI
Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...- Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and SyngeneMacquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressure...
- Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis...
- India's Everest Organics starts making ingredient for Merck's COVID-19 pillThe Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...
- Divi’s Lab Q4 results: Net profit rises 25% to Rs 488 cr, beats estimates; firm to pay Rs 20 dividendThe Hyderabad-based drugmaker’s total revenues in the quarter rose 20 per cent on-year to Rs 1,741 crore, which was slightly above analysts...
- Divi's Lab earmarks Rs 1,500 cr to set up manufacturing facility in Andhra PradeshDrugmaker Divi's Laboratories on Tuesday said it has earmarked Rs 1,500 crore to set up a new manufacturing facility in Andhra Pradesh. The...
- At Rs 58.8 cr, Murali of Divi's Lab highest paid Indian pharma executiveThe percentage increase in the median remuneration for the staff of the firm for FY19 was 3.96 per cent.
- Divis to spend Rs 300 crore on expansion plans in 2018The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during th...
- Market Now: Lupin drags Nifty Pharma index down by 4%21 stocks that hit fresh 52-week lows on NSE in Tuesday's trade so far.
- Pharma stocks gain amid govt's plans to crackdown on marketing by drug makersThe Nifty Pharma index emerged as the top gainer on NSE.
- IOC, REC mixed on MSCI inclusion, Divi’s Labs drops on exclusionShares of IOC climbed 2.03 per cent to hit a high of Rs 450.65 on BSE.
- FDA warns Divi's Labs over data integrity issues at Vizag unitIt further said methods, facilities, or controls for manufacturing, processing, packing or holding at the facility did not conform to CGMP.
- Fifteen stocks in focus on Thursday, 8 December 2016Drug firm Divi's Laboratories on Wednesday said the US health regulator has made five observations after inspection of its manufacturing pl...
- Divis Laboratories to invest Rs 500 crore to set up manufacturing plantThe drug maker has made an application to the Andhra Pradesh government for allotment of land near Kakinada and is awaiting favourable resp...
- Ranbaxy may launch generic of Novartis’ Diovan in US soonThis launch, pending since September 2012 when Novartis lost patent protection, could happen as early as May, one of the people quoted abov...
- Pharma companies grapple with rise in other expensesThe other expenses of these companies rose at a much higher pace than their revenues over the last three years, says a study.
- Ranbaxy slips to 8th position in market-capitalisationRanbaxy has slipped to eighth position and the current m-cap of Rs 14,620 crore is below its average m-cap for 2006.
- Weak rupee, exclusivity sales help pharma companies post strong performance in March quarterThe sector should gain further as more innovator companies are planning to outsource manufacturing of intermediates and bulk drugs to compa...
- Divi's Lab rises on reports of MSCI inclusionShares of Indian drug maker Divi's Laboratories rose over 2 percent on Tuesday, on reports of a possible inclusion in the MSCI index.
- Govt orders cost audit of pharma cos to check hefty trade marginsDrug makers who charge hefty margins will soon have to admit that.
Load More
